Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06208397
Recruiting Observational

MRE for Assessment of Histopathological Growth Patterns in Colorectal Liver Metastases

NCT06208397 · tracked via the Priya Life Science China tracker
Sponsor
Shengjing Hospital
Phase
Observational
Started
2023-12-24
Last updated
2025-05-15

Condition(s) studied

Metastatic Colorectal Cancer

Investigational drug(s) / intervention(s)

Magnetic Resonance Elastography and routine MRI

Magnetic Resonance Elastography and routine MRI: Assessed boundary conditions through MRE-base SII before surgery and recorded HGP of tumor after surgery.

Study summary

The goal of this study is to investigate the value of MR elastography-based SII as a means of detecting HGP noninvasively in patients with pathology-proven CRLM. MRE will provide a direct measure of tumor-liver adhesion to investigate the relationship between imaging findings and pathophysiological changes in the Liver.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Diagnosed CRLM * Pathologic results obtained in surgical patients * No contraindications for magnetic resonance imaging examination Exclusion Criteria: * Image quality does not meet the measurement requirements. * the diameter of CRLM \<1cm * Combined with other important organ dysfunction * Combined with malignant tumor * Patients who do not sign an informed consent * Patients with metallic implants or foreign bodies in their bodies (pacemakers, artificial metallic heart valves, metal joints, metal implants, and those who cannot remove dentures, insulin pumps, or contraceptive rings)

Primary outcome measure(s)

  • Radiological assessment of CRLM — Baseline to 6 weeks
    Examinations were performed on a 3.0T MRI. Mechanical vibration frequencies of 30 and 60 Hz were applied in synchrony with the MRE pulse sequence. Regions of interest (ROIs) were placed manually in the liver. The performance of the use of SII to predict HGP of tumor was evaluated with the Wilcoxon rank sum, 1-way ANOVA, and Tukey-Kramer tests.

Trial sites (1)

FacilityCityRegionStatus
Shengjing Hospital of China Medical University Shenyang Liaoning Recruiting

More Shengjing Hospital trials in China

An Observational Study About Adverse Outcomes in Acute Pulmonary Embolism Patients Active, not recruiting
MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B Recruiting
A Clinical Study of Hyperthyroidism in Children Recruiting
Combined Magnetic Stimulation and Ultrasound for Detrusor Overactivity in SCI Starting soon
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy Recruiting

Other trials for the same condition

New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer Recruiting
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer Recruiting
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation Recruiting
Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy Recruiting
A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06208397 on ClinicalTrials.gov ↗ ← All trials in China